Abstract:Research on CAR T cells has achieved enormous progress in recent years. After the impressive results obtained in relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell lymphomas, two constructs, tisagenlecleucel and axicabtagene ciloleucel, were approved by FDA. The role of CAR T cells in the treatment of B-cell disorders, however, is rapidly evolving. Ongoing clinical trials aim at comparing CAR T cells with standard treatment options and at evaluating their efficacy earlier in the disease course. The use of CAR T cells is still limited by the risk of relevant toxicities, most commonly cytokine release syndrome and neurotoxicity, whose management has nonetheless significantly improved. Some patients do not respond or relapse after treatment, either because of poor CAR T-cell expansion, lack of anti-tumor effects or after the loss of the target antigen on tumor cells. Investigators are trying to overcome these hurdles in many ways: by testing constructs which target different and/or multiple antigens or by improving CAR T-cell structure with additional functions and synergistic molecules. Alternative cell sources including allogeneic products (off-the-shelf CAR T cells), NK cells, and T cells obtained from induced pluripotent stem cells are also considered. Several trials are exploring the curative potential of CAR T cells in other malignancies, and recent data on multiple myeloma and chronic lymphocytic leukemia are encouraging. Given the likely expansion of CAR T-cell indications and their wider availability over time, more and more highly specialized clinical centers, with dedicated clinical units, will be required. Overall, the costs of these cell therapies will also play a role in the sustainability of many health care systems. This review will focus on the major clinical trials of CAR T cells in B-cell malignancies, including those leading to the first FDA approvals, and on the new settings in which these constructs are being tested. Besides, the most promising approaches to improve CAR T-cell efficacy and early data on alternative cell sources will be reviewed. Finally, we will discuss the challenges and the opportunities that are emerging with the advent of CAR T cells into clinical routine.

CAR T cell immunotherapy for human cancer

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells

From bench to bedside: the history and progress of CAR T cell therapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR T-cell immunotherapy: The path from the by-road to the freeway?

CAR T-Cell Therapy: Progress and Prospects

CAR T cells in solid tumors: challenges and opportunities

Adoptive T cell therapy for solid tumors: current landscape and future challenges

Adoptive Immunotherapy beyond CAR T-Cells

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

Challenges and new technologies in adoptive cell therapy